Amwins Expands Gene Therapy Coverage

Stock.adobe.com

Amwins Group Benefits is expanding its Gene Therapy Solutions program.¹ The existing program will now cover 15 gene and cell therapies. Alongside treatment reimbursement, the plan provides members with monitoring and coverage of FDA approvals for new gene therapies.

In a press release, Stealth Partner Group (an Amwins Company) CEO Harley Barnes said, “Our Gene Therapy Solutions program addresses the growing needs of employers. Expanding from GTS-5 to GTS-15 helps to ensure that our clients have the comprehensive support they need to face the high cost of gene therapy treatments, while making the process simpler and more efficient. We remain dedicated to offering the best solutions for cost containment, helping employers maximize their budgets while providing cutting-edge protection for their workforce."

In the same press release, Stealth Partner Group senior vice president Meredith Hunter added, “Gene therapy is transforming the lives of patients, but with costs for treatment reaching up to $4.25 million, this is a challenge that employers shouldn't face alone. Our GTS-15 program provides the critical support needed to keep employers ahead of these rising costs while ensuring the best care for their employees."

Amwins Group Benefits recently named a new president.² In August, the group appointed Riva Dumeny to the position, moving her from her previous position of chief operating officer. She succeeded Sam Fleet in the role.

In a press release issued at the time, Dumeny said, “I look forward to leading our Group Benefits team and continuing to collaborate with Amwins senior leadership to ensure the division's continued dedication to the success of our brokers and carriers. We have unparalleled, national scale and the right partnerships, while also offering local access, expertise, and service. I see it as my job to make sure we deliver a seamless experience across the country–and most importantly, remain dedicated to the incredible culture Amwins has built."

In the same press release, Amwins CEO Scott Purviance added, “While we make this announcement today, the succession plan for our Group Benefits division has been developed and was executed over several years – it's representative of the strategic way we operate according to our 150-year vision. Throughout her tenure, Riva has demonstrated an unparalleled ability to develop business and operational strategies and lead and motivate team members. With her at the helm of Group Benefits, we see a continuity of approach that will enable the division to grow and to continue executing at the highest level on behalf of clients."

Purviance commented on the previous president, Sam Fleet, saying, "We wouldn't be where we are today without Sam Fleet's leadership and vision over the past 24 years at Amwins. Sam has been instrumental in building the division through key M&A partnerships and creative product development initiatives.”

Fleet added, “I look forward to watching my Amwins colleagues continue to have tremendous success with Riva leading the division. Having been in a senior leadership role with the division and Amwins since the beginning, this transition is deeply personal for me. With that in mind, I can say with absolute confidence that passing the torch to Riva will result in even bigger and better things for our retail clients, for their insureds, and for the firm."

Sources

1. Amwins Group Benefits Expands Gene Therapy Solutions Program. Amwins. October 10, 2024. https://www.prnewswire.com/news-releases/amwins-group-benefits-expands-gene-therapy-solutions-program-302272046.html
2. Riva Dumeny Appointed President of Amwins Group Benefits Division. Amwins. August 7, 2024. Accessing October 10, 2024. https://www.prnewswire.com/news-releases/riva-dumeny-appointed-president-of-amwins-group-benefits-division-302216029.html